Citation Impact
Citing Papers
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family
2014
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
2013
Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology
2013
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer Statistics, 2021
2021 Standout
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2017
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design
2012
Acute Eosinophilic and Neutrophilic Pneumonia following Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin for Hepatocellular Carcinoma: A Case Report
2014
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
2016
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
2018
Direct-acting and host-targeting HCV inhibitors: current and future directions
2012
Treatment triumphs
2014 StandoutNatureNobel
Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
2016
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
2013
Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization
2014
Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”
2012
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Type I interferons in infectious disease
2015 Standout
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
2021
Hepatocellular carcinoma
2012 Standout
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis
2012
PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3
2010
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
2016
The role of resistance in HCV treatment
2012
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
2015
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Transarterial radioembolizationvschemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis
2016
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
2010
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018
Liver cancer: Approaching a personalized care
2015
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
2014
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
2016
Guarding the frontiers: the biology of type III interferons
2015
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin
2015 StandoutNobel
Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion
2016
Remodelling the extracellular matrix in development and disease
2014 Standout
Transarterial therapies for hepatocellular carcinoma
2011
Loco‐regional treatment of hepatocellular carcinoma†
2010
Management of HCC
2012
Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma
2011
Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT–pathologic correlation in 178 liver explants
2013
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
2017
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
2014
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
2014
Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma
2014
Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b
2017 StandoutNobel
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
2013
Treatment of intermediate-stage hepatocellular carcinoma
2014
Local-Regional Treatment of Hepatocellular Carcinoma
2011
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Clinical Utility of Des-γ-Carboxy Prothrombin Kinetics as a Complement to Radiologic Response in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
2012
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
2017
Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
2014
Prospective Randomized Comparison of Chemoembolization with Doxorubicin-Eluting Beads and Bland Embolization with BeadBlock for Hepatocellular Carcinoma
2009
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review
2014
Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
2015
Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery
2014
Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study
2011
Hepatocellular Carcinoma
2011 Standout
Bridging Locoregional Therapy for Hepatocellular Carcinoma Prior to Liver Transplantation
2008
Predictive Factors of Downstaging of Hepatocellular Carcinoma Beyond the Milan Criteria Treated with Intra-arterial Therapies
2012
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
2015
Hepatocellular carcinoma
2022 Standout
Hepatocellular carcinoma: a global view
2010
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
Targeted Therapies for Hepatocellular Carcinoma
2011
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Local and Regional Therapies for Hepatocellular Carcinoma
2020
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
2012 Standout
Hepatocellular Carcinoma
2019 Standout
Transarterial embolization as neo‐adjuvant therapy pretransplantation in patients with hepatocellular carcinoma
2013
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
A randomized placebo‐controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization
2017
Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients
2017 StandoutNobel
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
2014
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma
2013
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Interferon-Free Regimens in the Liver-Transplant Setting
2014
Identification of AP80978, a Novel Small-Molecule Inhibitor of Hepatitis C Virus Replication That Targets NS4B
2014 StandoutNobel
Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN ‐free treatment and future perspectives
2016
Seed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B Interaction
2014 StandoutNobel
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
2020
Transarterial Chemoembolization and Radioembolization
2014
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
2016
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
2016
New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development
2014
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Global cancer statistics, 2012
2015 Standout
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
2013
Works of M. Schuchmann being referenced
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
2009
Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma
2007
Correlation of Multislice CT and Histomorphology in HCC Following TACE: Predictors of Outcome
2008
The Programmed Death (PD)‐1/PD‐Ligand 1 Pathway Regulates Graft‐Versus‐Host‐Reactive CD8 T Cells After Liver Transplantation
2008
Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
2013
1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY
2013
101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2
2012